% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • samur999 samur999 May 26, 2009 12:48 PM Flag

    SMYTH is the Key!................

    calm down poppy, whatever bobby "bonus" savage announced is just as trustable as this guy himself. Talk more about proven track record. Where are facts and science merits of Smyth?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From the S&P report:

      Recent Developments
      On April 13, 2009, EPCT announced the appointment
      of A. Collier Smyth, M.D., former senior vice
      president of medical strategy-oncology at Bristol-
      Myers Squibb Company (BMS), to its Board of Directors.
      Prior to his recent retirement from BMS,
      Dr. Smyth led oncology medical affairs in the United
      States, including the U. S. life-cycle development
      of paclitaxel (Taxol), carboplatin (Paraplatin)
      and ifosfamide (Ifex). Most recently, he participated
      in the launch of multiple BMS oncology drugs,
      including cetuximab (Erbitux), dasatinib (Sprycel)
      and ixabepilone (Ixempra).

0.2601-0.0073(-2.73%)3:59 PMEDT